Overview

Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2024-08-28
Target enrollment:
Participant gender:
Summary
A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Pembrolizumab